Leerink Partners initiated coverage on Accolade with a new price target
$ACCD
Business Services
Consumer Discretionary
Leerink Partners initiated coverage of Accolade with a rating of Outperform and set a new price target of $16.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/28/2024 | $13.00 → $8.00 | Buy | Needham |
| 2/26/2024 | $16.00 | Outperform | Leerink Partners |
| 1/17/2024 | $16.00 → $14.00 | Neutral | DA Davidson |
| 1/3/2024 | $13.00 | Equal Weight | Barclays |
| 5/24/2023 | $16.50 | Neutral → Buy | BofA Securities |
| 4/12/2023 | $18.00 | Overweight | Stephens |
| 3/23/2023 | $16.00 | Neutral → Buy | Guggenheim |
| 2/9/2023 | $14.00 | Buy → Hold | Jefferies |
Needham reiterated coverage of Accolade with a rating of Buy and set a new price target of $8.00 from $13.00 previously
Leerink Partners initiated coverage of Accolade with a rating of Outperform and set a new price target of $16.00
DA Davidson resumed coverage of Accolade with a rating of Neutral and set a new price target of $14.00 from $16.00 previously
SCHEDULE 13G/A - Accolade, Inc. (0001481646) (Subject)
DEFA14A - Accolade, Inc. (0001481646) (Filer)
SCHEDULE 13D - Accolade, Inc. (0001481646) (Subject)
Welcomes Dr. Connie Hwang as chief medical officer, creates roles of chief health officer and chief nursing officer SEATTLE, Sept. 18, 2023 /PRNewswire/ -- Accolade (NASDAQ:ACCD) announced the expansion of its care delivery team, strengthening the company's ability to streamline healthcare experiences through physician-led advocacy. Connie Hwang, MD, MPH, joins Accolade to lead population health strategies for employers and health plans. Led by Shantanu Nundy, MD, executive vice president, chief health officer, the care delivery leadership team includes Dr. Hwang, senior vice president, chief medical officer; James Wantuck, MD, senior vice president, associate chief medical officer and co-fo
With the addition of senior vice president and CISO, Kelli Burns, Accolade further elevates its focus on trusted, personalized relationships through exceptional information security for its members and customers SEATTLE, July 25, 2022 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD), the company that provides millions of people and their families with Personalized Healthcare, announced today that Kelli Burns has joined the organization as senior vice president, chief information security officer. Burns, a former consultant with Ernst & Young LLP (EY US) focused on cybersecurity en
Accolade welcomes executive vice president and chief human resources officer Jennifer Hanson to create an amazing employee experience for the company that partners with human resource leaders to deliver Personalized Healthcare SEATTLE, May 2, 2022 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD), the company that provides millions of people and their families with exceptional healthcare, announced today the appointment of Jennifer Hanson as chief human resources officer, executive vice president of people and culture, reporting to Accolade CEO, Rajeev Singh. Hanson will oversee
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
Combined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment Transcarent's Generative AI WayFinding and care experiences combined with Accolade's Advocacy, Expert Medical Opinion, and Primary Care will deliver on the promise of ‘One Place for Health and Care' Accolade shareholders to receive $7.03 per share in cash SAN FRANCISCO and SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, announced that they have entered into a definitive agreement under which Transcarent wil
SEATTLE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal third quarter 2025 financial results on Thursday, January 9, 2024 after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here. (https://register.vevent.com/register/BI0dce2f02ed2f44c8901127623aa788c3) Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via a li
SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal second quarter ended August 31, 2024. "As we enter the second half of fiscal year 2025, we are well positioned to deliver our first full year of Adjusted EBITDA profitability and positive cash flow. Accolade is proving the scalability and profitability of a business model and strategy that is fundamentally designed to improve the lives of millions of people and their families. Our focus remains on solving the Physician Gap through a physician-led advocacy approach that engages the entire healthcare ecosystem and enables a better healthcare experience for our members," s
Combined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment Transcarent's Generative AI WayFinding and care experiences combined with Accolade's Advocacy, Expert Medical Opinion, and Primary Care will deliver on the promise of ‘One Place for Health and Care' Accolade shareholders to receive $7.03 per share in cash SAN FRANCISCO and SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, announced that they have entered into a definitive agreement under which Transcarent wil
SEATTLE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal third quarter 2025 financial results on Thursday, January 9, 2024 after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here. (https://register.vevent.com/register/BI0dce2f02ed2f44c8901127623aa788c3) Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via a li
SEATTLE, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will be presenting at the following upcoming investor events. A webcast will be available at ir.accolade.com and a replay will be available for 90 days. Stephens Annual Investment Conference | NASH2024 in Nashville on Wednesday, November 20 at 9:00 am CTCG MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21. (1x1 meetings, no webcast)Piper Sandler 36th Annual Healthcare Conference in New York on Thursday, December 5 at 10:00 am ET. About Accolade, Inc. Accolade (NASDAQ:ACCD) is a Personalized Healthcare company that provides millions of people and the
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G - Accolade, Inc. (0001481646) (Subject)